Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the... see more

Recent & Breaking News (NDAQ:IMNN)

Celsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire May 12, 2017

Technical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma

PR Newswire May 11, 2017

Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017

GlobeNewswire May 5, 2017

Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed  Advanced Ovarian Cancer Patients

GlobeNewswire May 4, 2017

Celsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting

GlobeNewswire April 20, 2017

Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Published in the International Journal of Hyperthermia

GlobeNewswire April 13, 2017

Biotech Stocks Under Scanner -- Celsion, Achillion Pharma, Tenax Therapeutics, and Cerulean Pharma

PR Newswire March 29, 2017

Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update

GlobeNewswire March 16, 2017

Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017

GlobeNewswire March 9, 2017

Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium

GlobeNewswire February 27, 2017

Celsion Corporation Announces $5.0 Million Public Offering

GlobeNewswire February 15, 2017

Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium

GlobeNewswire January 19, 2017

Celsion Corporation Announces Issuance of Two New Patents for ThermoDox®

GlobeNewswire January 18, 2017

Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients

GlobeNewswire January 17, 2017

Celsion Corporation Announces $1.8 Million Registered Direct Offering

GlobeNewswire December 20, 2016

Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer

GlobeNewswire December 1, 2016

Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA Study of ThermoDox® for Primary Liver Cancer

GlobeNewswire November 30, 2016

Celsion Corporation Announces Presentation of Results from Independent NIH Analysis of ThermoDox® plus Optimized RFA for the Treatment of Primary Liver Cancer at the 2016 RSNA Annual Meeting

GlobeNewswire November 29, 2016

Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Stage III and IV Ovarian Cancer Patients

GlobeNewswire November 10, 2016

Celsion Corporation Reports Third Quarter 2016 Financial Results and Provides Business Update

GlobeNewswire November 10, 2016